Stock listing
NYSE:NUVB Nuvation Bio Inc. Stock
Home listing (NYSE) of Nuvation Bio Inc.
Follow Nuvation Bio Inc. into a list and get an email when it puts out news.
Share price · NYSE:NUVB
$3.80 USD +0.02 (+0.5%)
Close on Nov 20, 2026
- Day range
- $3.72 – $3.91 USDNov 20, 2026
- Volume
- 6.85M sharesNov 20, 2026
- Market cap
- $1.34B USDAt the close on Nov 20, 2026 · price × 353.0M shares outstanding
- 52-week range
- $3.72 – $9.75 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $27.18M USDMedian day 4.84M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:NUVB · Home | $3.80 USD | +0.02 (+0.5%) | 6,848,938 | $3.77 | $3.91 | $3.72 | $3.78 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:NUVB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.80 | +0.02 | +0.5% | $3.77 | $3.91 | $3.72 | 6,848,938 | |
| $3.78 | -0.12 | -3.1% | $3.92 | $3.975 | $3.77 | 5,956,075 | |
| $3.90 | +0.06 | +1.6% | $3.80 | $3.98 | $3.788 | 5,752,952 | |
| $3.84 | -0.15 | -3.8% | $3.99 | $4.00 | $3.82 | 7,826,513 | |
| $3.99 | -0.07 | -1.7% | $4.03 | $4.115 | $3.945 | 3,086,620 | |
| $4.06 | -0.23 | -5.4% | $4.22 | $4.22 | $4.03 | 5,614,021 | |
| $4.29 | +0.09 | +2.1% | $4.27 | $4.375 | $4.22 | 2,951,650 | |
| $4.20 | -0.15 | -3.4% | $4.23 | $4.355 | $4.11 | 3,478,343 | |
| $4.35 | +0.19 | +4.6% | $4.23 | $4.43 | $4.075 | 5,326,427 | |
| $4.16 | -0.03 | -0.7% | $4.21 | $4.329 | $3.98 | 5,328,011 | |
| $4.19 | -0.54 | -11.4% | $4.459 | $4.81 | $4.18 | 8,419,216 | |
| $4.73 | +0.04 | +0.9% | $4.70 | $4.75 | $4.52 | 8,369,789 | |
| $4.69 | +0.10 | +2.2% | $4.62 | $4.785 | $4.61 | 5,141,344 | |
| $4.59 | -0.17 | -3.6% | $4.80 | $4.85 | $4.59 | 3,723,263 | |
| $4.76 | -0.01 | -0.2% | $4.75 | $4.805 | $4.60 | 5,059,887 | |
| $4.77 | +0.18 | +3.9% | $4.65 | $4.835 | $4.64 | 6,495,901 | |
| $4.59 | +0.04 | +0.9% | $4.48 | $4.60 | $4.425 | 5,213,784 | |
| $4.55 | +0.04 | +0.9% | $4.51 | $4.59 | $4.36 | 5,042,823 | |
| $4.51 | -0.06 | -1.3% | $4.62 | $4.68 | $4.48 | 3,660,066 | |
| $4.57 | -0.13 | -2.8% | $4.62 | $4.66 | $4.44 | 3,190,400 | |
| $4.70 | -0.15 | -3.1% | $4.83 | $4.91 | $4.655 | 5,805,100 | |
| $4.85 | +0.08 | +1.7% | $4.77 | $4.96 | $4.72 | 4,501,300 | |
| $4.77 | +0.29 | +6.5% | $4.51 | $4.82 | $4.46 | 6,853,000 | |
| $4.48 | +0.03 | +0.7% | $4.48 | $4.60 | $4.345 | 4,222,000 | |
| $4.45 | -0.30 | -6.3% | $4.75 | $4.76 | $4.42 | 4,471,300 | |
| $4.75 | +0.07 | +1.5% | $4.74 | $4.855 | $4.67 | 4,822,800 | |
| $4.68 | -0.04 | -0.8% | $4.66 | $4.80 | $4.61 | 3,779,000 | |
| $4.72 | -0.18 | -3.7% | $4.86 | $4.92 | $4.71 | 7,607,800 | |
| $4.90 | -0.10 | -2.0% | $4.96 | $5.005 | $4.88 | 3,182,900 | |
| $5.00 | +0.05 | +1.0% | $4.95 | $5.06 | $4.87 | 2,957,000 | |
| $4.95 | +0.09 | +1.9% | $4.80 | $4.98 | $4.625 | 9,289,800 | |
| $4.86 | -0.02 | -0.4% | $4.81 | $4.95 | $4.79 | 5,448,700 | |
| $4.88 | -0.07 | -1.4% | $4.96 | $4.97 | $4.73 | 6,653,200 | |
| $4.95 | -0.19 | -3.7% | $5.12 | $5.16 | $4.85 | 9,963,000 | |
| $5.14 | -0.42 | -7.6% | $5.66 | $5.66 | $5.03 | 14,825,000 | |
| $5.56 | -0.04 | -0.7% | $5.57 | $5.616 | $5.452 | 3,471,200 | |
| $5.60 | -0.02 | -0.4% | $5.81 | $5.825 | $5.59 | 5,547,000 | |
| $5.62 | +0.02 | +0.4% | $5.59 | $5.69 | $5.54 | 3,068,000 | |
| $5.60 | -0.14 | -2.4% | $5.68 | $5.68 | $5.48 | 4,584,700 | |
| $5.74 | +0.01 | +0.2% | $5.73 | $5.825 | $5.67 | 2,816,600 | |
| $5.73 | +0.02 | +0.4% | $5.69 | $5.78 | $5.535 | 5,705,600 | |
| $5.71 | -0.39 | -6.4% | $6.07 | $6.07 | $5.69 | 4,603,900 | |
| $6.10 | +0.03 | +0.5% | $6.26 | $6.26 | $5.955 | 4,323,000 | |
| $6.07 | +0.22 | +3.8% | $6.00 | $6.105 | $5.86 | 3,026,200 | |
| $5.85 | -0.22 | -3.6% | $6.15 | $6.18 | $5.82 | 4,433,900 | |
| $6.07 | +0.29 | +5.0% | $5.96 | $6.16 | $5.92 | 5,738,500 | |
| $5.78 | -0.02 | -0.3% | $5.80 | $5.82 | $5.655 | 2,781,200 | |
| $5.80 | -0.14 | -2.4% | $5.90 | $5.91 | $5.63 | 7,051,900 | |
| $5.94 | -0.13 | -2.1% | $5.90 | $6.135 | $5.77 | 10,029,800 | |
| $6.07 | -0.21 | -3.3% | $6.36 | $6.39 | $5.95 | 4,318,000 | |
| $6.28 | -0.24 | -3.7% | $6.44 | $6.45 | $6.17 | 7,979,800 | |
| $6.52 | -0.09 | -1.4% | $6.55 | $6.715 | $6.50 | 2,611,400 | |
| $6.61 | -0.20 | -2.9% | $6.69 | $6.746 | $6.58 | 2,541,900 | |
| $6.81 | +0.04 | +0.6% | $6.78 | $6.87 | $6.72 | 3,755,200 | |
| $6.77 | -0.16 | -2.3% | $7.03 | $7.13 | $6.65 | 5,266,900 | |
| $6.93 | +0.29 | +4.4% | $6.75 | $6.97 | $6.69 | 4,996,700 | |
| $6.64 | -0.02 | -0.3% | $6.60 | $6.95 | $6.58 | 4,843,600 | |
| $6.66 | 0.00 | 0.0% | $6.695 | $6.753 | $6.485 | 3,199,800 | |
| $6.66 | -0.33 | -4.7% | $6.90 | $6.996 | $6.625 | 3,662,000 | |
| $6.99 | +0.03 | +0.4% | $6.91 | $7.18 | $6.88 | 3,530,300 | |
| $6.96 | -0.14 | -2.0% | $7.09 | $7.12 | $6.91 | 3,439,000 | |
| $7.10 | +0.34 | +5.0% | $6.93 | $7.13 | $6.855 | 4,154,798 | |
| $6.76 | -0.17 | -2.5% | $6.82 | $6.97 | $6.66 | 3,015,226 | |
| $6.93 | +0.10 | +1.5% | $6.98 | $7.09 | $6.88 | 6,035,800 | |
| $6.83 | -0.43 | -5.9% | $7.31 | $7.31 | $6.76 | 5,312,500 |
- Ticker
- NYSE:NUVB
- Asset type
- Stock
- Exchange
- NYSE
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
Latest earnings call · Nov 4, 2026
Nuvation Bio (NYSE:NUVB) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 6, 2026
Q2 2026 Earnings Presentation
Earnings · 34 slides
Latest news
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
Nov 16, 2026
Closed $3.84 (-3.8%) on Nov 16, 2026
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London
Nov 10, 2026
Closed $4.29 (+2.1%) on Nov 11, 2026
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 4, 2026
Closed $4.19 (-11.4%) on Nov 5, 2026
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting
Nov 2, 2026
Closed $4.59 (-3.6%) on Nov 2, 2026
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
Oct 29, 2026
Closed $4.77 (+3.9%) on Oct 29, 2026
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
Oct 21, 2026
Closed $4.70 (-3.1%) on Oct 22, 2026
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Sep 16, 2026
Closed $5.78 (-0.3%) on Sep 16, 2026
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
Sep 15, 2026
Closed $5.80 (-2.4%) on Sep 15, 2026
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
Aug 20, 2026
Closed $6.83 (-5.9%) on Aug 20, 2026
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026
Closed $6.11 (-4.1%) on Aug 6, 2026
Nuvation Bio Inc. on 6ix
- News releases
- 36 in the last 12 months · 58 in all · newest Nov 16, 2026 · oldest 2025
- Calls
- 6 calls with a replay · 6 with a transcript · latest Nov 4, 2026
- Decks
- 20 decks · latest Aug 6, 2026
Where Nuvation Bio Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:NUVB · Home listing · This page | NYSE | United States | USD |
| BOATS:NUVB | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $963.5M USD
- P/E
- Loss
- EV/sales
- 4.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.9×
- Gross margin
- 90.6%
- Operating margin
- −61.2%
- Net margin
- −67.4%
- Debt to equity
- 1.3×
- Beta vs S&P 500
- 1.49
Forecasts
9 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.45 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.29 · 2 analysts
- Revenue, year to Dec 2026
- 203.2M · 13 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David Hung | Founder, President and Chief Executive Officer |
| Philippe Sauvage | Chief Financial Officer |
| Stephen Dang | Chief Legal Officer |
| Eisai Co | Ltd. Investor Relations Department |
| Colleen Sjogren | Chief Commercial Officer |
| David Hanley | Chief Technical Operations Officer |
| Gary Hattersley | Chief Scientific Officer |
| Kerry Wentworth | Chief Regulatory Officer |
| Stacy Markel | Chief People Officer |
Board
| Director | Role |
|---|---|
| David Hung | Founder, President and Chief Executive Officer |
| Junyuan Jerry Wang | Board of Directors |
| Kathryn Falberg | Board of Directors |
| Kim D. Blickenstaff | Board of Directors |
| Min Cui | Board of Directors |
| Robert Bazemore | Lead Independent Director, Board of Directors |
| Robert Mashal | Board of Directors |
| W. Anthony Vernon | Board of Directors |
Events
Calls
| Call | When | Status |
|---|---|---|
| Nuvation Bio (NYSE:NUVB) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 4:30 PM ET | Replay |
| Nuvation Bio (NYSE:NUVB) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 8:00 AM ET | Replay |
| Nuvation Bio (NYSE:NUVB) Q1 2026 Earnings Call | Mon, May 04, 2026 · 4:30 PM ET | Replay |
| Nuvation Bio (NYSE:NUVB) Q3 2025 Earnings Call | Mon, Nov 03, 2025 · 4:30 PM ET | Replay |
| Nuvation Bio (NYSE:NUVB) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:00 AM ET | Replay |
| Nuvation Bio (NYSE:NUVB) Q1 2025 Earnings Call | Wed, May 07, 2025 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −11.4% |
| Q2 2026 | Aug 6, 2026 · Before open | −4.1% |
| Q1 2026 | May 4, 2026 · After close | +9.5% |
| Q4 2025 | Mar 2, 2026 | −26.2% |
| Q3 2025 | Nov 3, 2025 · After close | −6.6% |
| Q2 2025 | Aug 7, 2025 · Before open | −0.4% |
| Q1 2025 | May 7, 2025 · After close | +2.9% |
| Q4 2024 | Feb 26, 2025 · Before open | −3.4% |
| Q3 2024 | Nov 6, 2024 · After close | +3.1% |
| Q2 2024 | Aug 5, 2024 · Before open | −5.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | 0.0% |
| Q4 2023 | Feb 29, 2024 · After close | +19.3% |
| Q3 2023 | Nov 2, 2023 · After close | +5.5% |
| Q2 2023 | Aug 3, 2023 · After close | +4.5% |
| Q1 2023 | May 4, 2023 · After close | +3.1% |
| Q4 2022 | Mar 15, 2023 · After close | +2.4% |
| Q3 2022 | Nov 3, 2022 · After close | −2.3% |
| Q2 2022 | Aug 4, 2022 · After close | +5.1% |
| Q1 2022 | May 9, 2022 · After close | +4.7% |
| Q4 2021 | Feb 28, 2022 · After close | −3.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Aug 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 34 slides | May 4, 2026 |
| Investor Presentation (January 2026) | Investor deck | 37 slides | January 2026 |
| Investor Presentation (November 2025) | Investor deck | 36 slides | Nov 26, 2025 |
| Investor Presentation (November 2025) | Investor deck | 39 slides | Nov 17, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 6 slides | Aug 7, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 38 slides | Aug 7, 2025 |
| Investor Presentation (June 2025) | Investor deck | 37 slides | Jun 11, 2025 |
| Technical Presentation (May 2025) | Technical | 10 slides | May 7, 2025 |
| TD Cowen 45th Annual Health Care Conference 2025 | Conference | 40 slides | Mar 3, 2025 |
All 20 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 43rd Annual J.P. Morgan Healthcare Conference (January 2025) | Conference | 27 slides | Jan 13, 2025 |
| Investor Presentation (October 2024) | Investor deck | 40 slides | October 2024 |
| Merger or Acquisition (March 2024) | Merger or acquisition | 14 slides | Mar 25, 2024 |
| Investor Presentation (November 2023) | Investor deck | 28 slides | November 2023 |
| Investor Presentation (August 2023) | Investor deck | 28 slides | August 2023 |
| Investor Presentation (December 2022) | Investor deck | 33 slides | Dec 23, 2022 |
| Investor Presentation (January 2022) | Investor deck | 55 slides | Jan 10, 2022 |
| Investor Presentation (March 2021) | Investor deck | 54 slides | March 2021 |
| Panacea Acquisition — SPAC Merger (January 2021) | SPAC merger | 58 slides | Jan 5, 2021 |
| SPAC Merger (October 2020) | SPAC merger | 47 slides | Oct 21, 2020 |
Financings
| Raise | Date |
|---|---|
| 0.75% Convertible Senior Notes due 2032 Closed: US$287.5M raised Use of proceeds: Pay about $2.2 million for additional capped call transactions; remainder for general corporate purposes including working capital and operating expenses | Jul 6, 2026 |
| 0.75% Convertible Senior Notes due 2032 Made bigger: US$250M · Jefferies LLC +3 Dealers: Jefferies LLC (co-lead), Citigroup (co-lead), Cantor Fitzgerald & Co. (co-lead), RBC Capital Markets, LLC Use of proceeds: Pay for capped call transactions, repay in full its senior secured loan agreement, and general corporate purposes | Jun 26, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Panacea Acquisition Corp, a blank check company (SPAC). Priced at US$10.00 a unit on Jun 30, 2020.
- Price
- US$10.00 a unit
- Units offered
- 12,500,000 units
- Offering size
- US$125 million
- Underwriters' option
- Up to 1,875,000 more units
- Listing
- PANA.U on the New York Stock Exchange
- Underwriter
- Cowen
- Units delivered
- On or about Jul 6, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 15, 2020 |
| Filed publicly | Jun 12, 2020 |
| Amended once | Jun 23, 2020 |
| Shares registered with an exchange | Jun 26, 2020 |
| Declared effective by the SEC | Jun 30, 2020 |
| Final prospectus, with the price | Jul 2, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 2, 2020 |
| EFFECT · Notice that a registration is effective | Jun 30, 2020 |
| CERT · Exchange's certificate of listing | Jun 29, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 26, 2020 |
| S-1/A · Registration statement, amended | Jun 23, 2020 |
| S-1 · Registration statement | Jun 12, 2020 |
| DRS · Draft registration statement | May 15, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 2, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 62.9M | 7.87M | 0 | 0 | 0 | 0 | ||
| Cost of revenue | 8.44M | 7.08M | 0 | 484.0K | 368.0K | 103.0K | ||
| Gross profit | 54.5M | 795.0K | 0 | -484.0K | -368.0K | -103.0K | ||
| Research and development | 115.1M | 99.1M | 71.3M | 87.8M | 69.0M | 32.6M | 25.1M | 482.7K |
| Selling, general and administrative | 151.6M | 69.2M | 28.5M | 31.9M | 24.3M | 10.9M | 6.59M | 509.3K |
| Operating income | -213.1M | -592.6M | -99.8M | -119.7M | -93.3M | -43.6M | -32.1M | -992.0K |
| Depreciation and amortization | 1.74M | 683.0K | 222.0K | 199.0K | 184.0K | 103.0K | 13.0K | 992.0K |
| EBITDA | -211.3M | -591.9M | -99.6M | -119.5M | -93.1M | -43.4M | -32.1M | 0 |
| Interest expense | 13.7M | 341.0K | 0 | 9.16M | 644.0K | 0 | 0 | 0 |
| Income before tax | -204.6M | -567.9M | -75.8M | -104.2M | -86.8M | -41.7M | -33.6M | -992.0K |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Net income | -204.6M | -567.9M | -75.8M | -104.2M | -86.8M | -41.7M | -33.6M | -992.0K |
| Earnings per share, basic | -0.60 | -2.11 | -0.35 | -0.48 | -0.44 | -0.43 | -0.16 | -0.01 |
| Earnings per share, diluted | -0.60 | -2.11 | -0.35 | -0.48 | -0.44 | -0.43 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 164.1M | 35.7M | 42.6M | 101.1M | 132.4M | 29.8M | 3.47M | 138.0K |
| Short-term investments | 365.1M | 467.0M | 568.6M | 559.9M | 633.0M | 186.0M | 115.4M | |
| Receivables | 19.4M | 16.3M | 3.70M | 2.48M | 3.04M | 1.09M | 828.0K | |
| Inventory | 11.4M | 0 | 643.1M | 2.92M | ||||
| Current assets | 571.5M | 526.3M | 616.4M | 667.3M | 772.1M | 220.7M | 119.9M | 158.0K |
| Property, plant and equipment | 564.0K | 586.0K | 717.0K | 894.0K | 786.0K | 688.0K | 646.0K | |
| Total assets | 594.8M | 540.6M | 621.5M | 672.1M | 776.2M | 221.8M | 121.0M | 158.0K |
| Accounts payable | 9.48M | 6.35M | 2.21M | 2.14M | 3.92M | 2.17M | 2.03M | 83.0K |
| Current liabilities | 82.2M | 58.2M | 14.0M | 13.2M | 16.9M | 6.55M | 3.20M | 902.0K |
| Long-term debt | 47.2M | |||||||
| Total debt | 52.9M | 8.91M | 4.01M | 4.26M | 3.06M | 600.0K | ||
| Total liabilities | 289.1M | 76.8M | 16.4M | 17.1M | 30.2M | 6.71M | 3.20M | 902.0K |
| Shareholders' equity | 305.7M | 463.8M | 605.1M | 655.1M | 746.0M | 215.1M | 117.7M | -744.0K |
| Shares outstanding | 346.5M | 337.8M | 219.0M | 218.6M | 217.9M | 149.0M | 206.7M | 183.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -173.4M | -130.4M | -68.0M | -96.1M | -68.2M | -36.5M | -24.4M | -616.0K |
| Capital spending | -354.0K | -162.0K | -69.0K | -370.0K | -282.0K | -145.0K | -659.0K | -659.0K |
| Free cash flow | -173.8M | -130.6M | -68.1M | -96.5M | -68.5M | -36.7M | -25.1M | -616.0K |
| Cash from investing | 99.5M | 122.7M | 8.92M | 63.5M | -454.7M | -70.3M | -115.9M | -115.9M |
| Cash from financing | 202.5M | 331.0K | 628.0K | 1.33M | 625.5M | 133.1M | 143.6M | 800.0K |
| Share buybacks | 939.0K | 758.0K | 135.7M | |||||
| Change in cash | 128.4M | -6.93M | -58.5M | -31.3M | 102.7M | 26.3M | 3.33M | 184.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 6, 2026 | Financing | SEC |
| 8-K · Current report | Jun 30, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 26, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 305B2 | Jun 26, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | Jun 26, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jun 25, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | May 27, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 26, 2026 | Insider trade | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 4, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 17, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 10, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 3, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 2, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 2, 2026 | Results | SEC |
| 25-NSE | Feb 10, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 26, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 3, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 8-K · Current report | May 23, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 2, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 8, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 8, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 25, 2025 | Material contract | SEC |
| S-3ASR · Registration statement | Mar 6, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Results | SEC |
| 8-K · Current report | Mar 5, 2025 | Material contract | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 12, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 7, 2024 | Management or board change | SEC |
| SC 13D · Big-stake notice | Sep 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 5, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 16, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Aug 15, 2024 | Offer document | SEC |
| DEFR14A | Aug 13, 2024 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Aug 12, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 8, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 5, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Jul 30, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 30, 2024 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Jul 16, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 16, 2024 | Other filings | SEC |
| PRER14A | Jul 16, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 8-K/A · Current report, amended | Jun 20, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Jun 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jun 10, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| PRER14A | May 24, 2024 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | May 24, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 26, 2024 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Apr 18, 2024 | Offer document | SEC |
| 4 · Change in ownership | Apr 11, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 10, 2024 | Acquisition or disposal | SEC |
| 3 · Initial statement of ownership | Apr 2, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 26, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 25, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Mar 4, 2024 | Offer document | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 29, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 14, 2023 | Management or board change | SEC |
| 3 · Initial statement of ownership | Nov 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 27, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 13, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 2, 2023 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | Sep 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 3, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2023 | Results | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
This page holds 200 of 400 filings. Open Filings
Cap table
Built by 6ix from Nuvation Bio Inc.’s releases · as of Oct 30, 2026
- Common shares
- 353,017,638
- Fully diluted
- 353,017,638
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 353,017,638 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 353,017,638 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kathryn Falberg Other companies: Arcus Biosciences, Inc. (Board Member · Since at least Mar 14, 2018); The Trade Desk, Inc. (Director · Since at least Sep 20, 2016); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Jun 7, 2021 · Past); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Sio Gene Therapies Inc (Director · Apr 7, 2017 – May 15, 2017 · Past); BioMarin Pharmaceutical Inc. (Director · Jul 15, 2016 – Jul 15, 2016 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 24, 2016 · Past); Medivation Inc (Director · Jan 31, 2013 – Sep 28, 2016 · Past); Jazz Pharmaceuticals plc (EVP and CFO · Dec 1, 2009 – Mar 5, 2014 · Past); Novelion Therapeutics Inc (Director · Mar 25, 2009 – May 26, 2011 · Past); Oruka Therapeutics, Inc. (CFO and COO · Feb 23, 2009 – Jun 25, 2009 · Past); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – May 4, 2016 · Past) | Board of Directors · Since at least Feb 10, 2021 |
| Daniel Bradbury Other companies: Vivani Medical, Inc. (Member of the Board · Since at least Mar 4, 2024); Castle Biosciences, Inc. (Board Chairman · Since at least Jul 24, 2019); Equillium, Inc. (Chairman of the Board · Since at least Oct 11, 2018); Intercept Pharmaceuticals Inc (Director · Jul 19, 2016 – Nov 8, 2023 · Past); BioMed Realty Trust (Director · Jan 1, 2013 – Jan 27, 2016 · Past); Corcept Therapeutics Incorporated (Director · Oct 10, 2012 – Feb 7, 2019 · Past); Geron Corporation (Director · Sep 26, 2012 – Mar 29, 2019 · Past); Illumina, Inc. (Director · Jun 8, 2006 – May 25, 2017 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Feb 13, 2008 · Past); Amylin Pharmaceuticals LLC (President & Chief Executive Of, Director · Jan 5, 2006 – Feb 22, 2012 · Past) | Director · Jun 30, 2020 – Feb 10, 2021 · Past |
| Faheem Hasnain Other companies: Aspen Neuroscience, Inc. (Aspen Executive Chairman · Since at least Nov 2, 2026); Gossamer Bio, Inc. (Co-Founder, Chairman, and Chief Executive Officer · Since at least Feb 7, 2019); Kura Oncology, Inc. (Lead Independent Director · Since at least Apr 23, 2015); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Immunic, Inc. (Director · Aug 11, 2016 – Sep 13, 2018 · Past); Ambit Biosciences Corp (Director · May 15, 2013 – Nov 10, 2014 · Past); Receptos Inc (President & CEO, Director · May 8, 2013 – Aug 25, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Sep 16, 2010 – Dec 31, 2012 · Past); Facet Biotech Corp (President & CEO, Director · Dec 9, 2008 – Apr 21, 2010 · Past); PDL BioPharma Inc (President & CEO, Director · Oct 1, 2008 – Oct 1, 2008 · Past) | Director · Jun 30, 2020 – Feb 10, 2021 · Past |
| Daniel G. Welch Other companies: Prothena Corporation plc (Chair of the Board · Since at least Feb 21, 2024); Structure Therapeutics, Inc. (Director · Since at least Feb 2, 2023); Ultragenyx Pharmaceutical Inc. (Director · Since at least Apr 8, 2015); AveXis Inc (Director · Feb 10, 2016 – May 15, 2018 · Past); Intercept Pharmaceuticals Inc (Director · Nov 24, 2015 – May 28, 2020 · Past); Corium International Inc (Director · Apr 2, 2014 – Apr 2, 2014 · Past); Hyperion Therapeutics Inc (Director · Aug 23, 2012 – May 7, 2015 · Past); Seagen Inc (Director · Jun 13, 2007 – Dec 14, 2023 · Past); InterMune Inc (Chairman, CEO and President, Director · Mar 15, 2006 – Sep 29, 2014 · Past) | Director · Feb 10, 2021 – May 24, 2024 · Past |
| Graham Cooper Other companies: Beam Therapeutics Inc. (Director · Since at least Feb 5, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Applied Molecular Transport Inc (Director · Jun 4, 2020 – Jan 27, 2022 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Assembly Biosciences, Inc. (See Remarks · Mar 8, 2018 – Mar 29, 2019 · Past); Eiger Biopharmaceuticals Inc (Director · Jan 29, 2014 – Jun 4, 2015 · Past); Receptos Inc (Chief Financial Officer · May 8, 2013 – Aug 27, 2015 · Past); Geron Corporation (EVP, Bus Dev & CFO · Jan 5, 2012 – May 17, 2012 · Past); Orexigen Therapeutics Inc (CFO and Treasurer · Apr 25, 2007 – Jan 18, 2011 · Past) | Director · Jun 30, 2020 – Feb 10, 2021 · Past |
| Shalini Sharp Other companies: Iambic Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Septerna, Inc. (Director · Since at least Oct 24, 2024); Organon & Co. (Director · Since at least May 14, 2021); Neurocrine Biosciences, Inc. (Director · Since at least Feb 1, 2020); Precision BioSciences, Inc. (Director · Mar 27, 2019 – May 10, 2021 · Past); Sutro Biopharma, Inc. (Director · Nov 8, 2018 – Jun 6, 2022 · Past); Ultragenyx Pharmaceutical Inc. (EVP, Finance · Jan 30, 2014 – Oct 14, 2020 · Past); Agenus Inc. (Director · Oct 1, 2006 – Mar 2, 2018 · Past) | Director · Jun 30, 2020 – Feb 10, 2021 · Past |
| Oleg Nodelman Other companies: Theravance Biopharma, Inc. (BSFS · Since at least Nov 5, 2026); Aktis Oncology, Inc. (Director · Since at least Jan 8, 2026); Zymeworks Inc. (Director · Since at least Feb 17, 2025); AnaptysBio, Inc. (Member of the Nominating and Corporate Governance Committee · Since at least Apr 8, 2021); Panacea Acquisition II Corp (Director · Apr 6, 2020 – Apr 28, 2023 · Past); Prothena Corporation plc (Director · Dec 3, 2019 – Dec 3, 2019 · Past); Kindred Biosciences Inc (Director · Dec 11, 2013 – Sep 29, 2014 · Past) | Director · Jun 30, 2020 – Sep 19, 2023 · Past |
| David Hung Other companies: NovoCure Limited (Director · Since at least May 31, 2018); ARYA Sciences Acquisition Corp (Director · Oct 5, 2018 – Jul 1, 2020 · Past); Establishment Labs Holdings Inc. (Director · Jul 18, 2018 – May 26, 2020 · Past); Sio Gene Therapies Inc (Principal Executive Officer, Director · Apr 7, 2017 – Dec 29, 2017 · Past); Acer Therapeutics Inc (Director · May 15, 2006 – Apr 5, 2011 · Past); Medivation Inc (President and CEO, Director · Apr 5, 2005 – Sep 28, 2016 · Past) | Founder, President and Chief Executive Officer · Since at least Feb 10, 2021 |
| Robert Bazemore Other companies: Akari Therapeutics PLC (Director · Since at least Sep 17, 2024); Ardelyx, Inc. (Director · Since at least Jun 2, 2016); Epizyme Inc (President & CEO, Director · Sep 10, 2015 – Mar 25, 2021 · Past); Synageva BioPharma Corp (Chief Operating Officer · Sep 22, 2014 – Jun 22, 2015 · Past) | Lead Independent Director, Board of Directors · Since at least Feb 10, 2021 |
| Jennifer Fox Other companies: Zenas BioPharma, Inc. (See Remarks · Since at least Sep 12, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); ProKidney Corp. (Director · Since at least Jul 11, 2022) | Chief Financial Officer · Feb 10, 2021 – Feb 28, 2023 · Past |
All 33 people
| Person | Seat |
|---|---|
| Scott Platshon Other companies: Theravance Biopharma, Inc. (Executive Vice President and Chief Business Officer · Since at least Nov 4, 2026); Zymeworks Inc. (Executive Vice President and Chief Business Officer · Since at least Feb 22, 2024); Panacea Acquisition II Corp (Chief Operating Officer · Apr 6, 2021 – Apr 6, 2021 · Past) | Chief Operating Officer · Jun 30, 2020 – Jun 30, 2020 · Past |
| W. Anthony Vernon Other companies: McCormick & Company, Incorporated (Director · Since at least Mar 15, 2018); NovoCure Limited (Director · Since at least May 31, 2017); Intersect ENT Inc (Director · Jun 5, 2018 – Jun 4, 2020 · Past) | Director · Since at least Feb 10, 2021 |
| Xiangmin Cui Other companies: Alpine Immune Sciences Inc (Director · Jan 18, 2019 – May 18, 2024 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); China Biologic Products Holdings Inc (Director · Feb 4, 2010 – Jan 1, 2011 · Past) | Director · Since at least Apr 9, 2024 |
| Eisai Co Other companies: Eisai Co., Ltd. (Ltd. Investor Relations Department · Since at least Mar 26, 2026); Biogen Inc. (Investor Relations Department · Since at least Jan 25, 2026) | Ltd. Investor Relations Department · Since at least Mar 26, 2026 |
| Kerry Wentworth Other companies: Flexion Therapeutics Inc (Chief Regulatory Officer · Dec 21, 2017 – Nov 19, 2021 · Past); Agenus Inc. (VP, Clinical, Reg & Qual · Jul 20, 2006 – Feb 26, 2014 · Past) | Chief Regulatory Officer · Since at least May 23, 2022 |
| Kim D. Blickenstaff Other companies: OPY Acquisition I Corp (Director · Oct 26, 2021 – Oct 26, 2021 · Past); Tandem Diabetes Care, Inc. (Director · Nov 10, 2020 – Nov 20, 2024 · Past) | Director · Since at least Feb 10, 2021 |
| Michelle Doig Other companies: BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); Omega Alpha SPAC (President, Director · Jan 6, 2021 – Jan 6, 2021 · Past) | Director · Feb 10, 2021 – Feb 10, 2021 · Past |
| Sergey Yurasov Other companies: Black Diamond Therapeutics, Inc. (CHIEF MEDICAL OFFICER · Since at least Jun 10, 2022); Immune Design Corp (Sr. VP, Clinic. Devel. & CMO · Oct 1, 2016 – Apr 2, 2019 · Past) | Chief Medical Officer · Feb 10, 2021 – Feb 10, 2021 · Past |
| Thomas Templeman Other companies: Centessa Pharmaceuticals PLC (Chief Technology Officer · May 27, 2021 – Mar 31, 2023 · Past); Medivation Inc (SVP, Pharmaceutical Operations · Sep 29, 2015 – Sep 29, 2015 · Past) | SVP, Pharmaceutical Ops · Feb 10, 2021 – Feb 10, 2021 · Past |
| Caroline Stout Other companies: Panacea Acquisition II Corp (Chief Investment Officer · Apr 6, 2021 – Apr 6, 2021 · Past) | Chief Investment Officer · Jun 30, 2020 – Jun 30, 2020 · Past |
| Gary Hattersley Other companies: Radius Health, Inc. (Chief Scientific Officer · May 17, 2011 – Dec 31, 2018 · Past) | Chief Scientific Officer · Since at least Feb 10, 2021 |
| Sarah Marriott Other companies: Panacea Acquisition II Corp (Secretary, Director · Apr 6, 2021 – Apr 6, 2021 · Past) | Secretary, Director · Jun 30, 2020 – Jun 30, 2020 · Past |
| Scott Perlen Other companies: Panacea Acquisition II Corp (Chief Financial Officer · Apr 6, 2021 – Apr 6, 2021 · Past) | Chief Financial Officer · Jun 30, 2020 – Jun 30, 2020 · Past |
| Stacy Markel Other companies: Rigel Pharmaceuticals, Inc. (EVP Human Resources · Mar 19, 2018 – Mar 20, 2019 · Past) | Chief People Officer · Since at least Feb 10, 2021 |
| Colleen Sjogren | Chief Commercial Officer · Since at least Mar 27, 2024 |
| David Hanley | Chief Technical Operations Officer · Since at least Jun 1, 2021 |
| Dongfang Liu | CHIEF MEDICAL OFFICER · Since at least Jul 15, 2022 |
| Junyuan Jerry Wang | Board of Directors · Since at least Apr 9, 2024 |
| Min Cui | Board of Directors · Since at least Nov 5, 2026 |
| Moses Makunje | SEE REMARKS · Since at least Nov 27, 2023 |
| Philippe Sauvage | Chief Financial Officer · Since at least Oct 7, 2024 |
| Robert Mashal | Board of Directors · Since at least Jan 8, 2024 |
| Stephen Dang | Chief Legal Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Nuvation Bio Inc.